Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Akero Therapeutics (AKRO – Research Report), boosting the price target to $75.00.
Ed Arce’s rating is based on several promising developments at Akero Therapeutics. The company’s Phase 3 SYNCHRONY program is progressing well, with top-line data from the SYNCHRONY Histology study expected in the first half of 2027. This study is crucial as it evaluates efruxifermin (EFX) in patients with pre-cirrhotic MASH and aims to support accelerated approval by demonstrating significant improvements in fibrosis and MASH resolution.
Additionally, Akero’s financial position is strong, with a cash runway extending into 2028, which provides a solid foundation for ongoing research and development. The positive results from the Phase 2b SYMMETRY study in patients with compensated cirrhosis have also bolstered confidence, showing a significant response rate in fibrosis improvement. These factors collectively support Ed Arce’s Buy rating for Akero Therapeutics, as the company is well-positioned for future success in its clinical endeavors.
According to TipRanks, Arce is a 5-star analyst with an average return of 16.1% and a 47.35% success rate. Arce covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics, Ultragenyx Pharmaceutical, and Akero Therapeutics.
In another report released on February 28, Bank of America Securities also maintained a Buy rating on the stock with a $63.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com